Fulvestrant trials for Hormone-receptor-positive Breast Cancer

All Fulvestrant trials · All Hormone-receptor-positive Breast Cancer trials

Phase breakdown

Recruiting trials studying Fulvestrant for Hormone-receptor-positive Breast Cancer

• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
  NCT05524584 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
  NCT06756932 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• VS-6766+Abema+Fulv in Met HR+/HER- BC
  NCT05608252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations

Common questions

How many trials study Fulvestrant for Hormone-receptor-positive Breast Cancer?

6 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.